In 2024, Bristol-Myers Squibb completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Bristol-Myers Squibb has also provided a category-level breakdown for 10 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021-2019 |
|---|---|---|---|---|
Total Scope 1 | 206,726a | 208,534a | 212,280a | |
Total Scope 2 | ||||
Market-Based | 104,649a | 158,447a | 160,554a | |
Location-Based | 149,836a | 158,817a | 155,056a | |
Total Scope 3 | 1,700,746a | 1,750,947a | 1,768,500a | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 4.28a | 4.6335a | 4.5989a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Bristol-Myers Squibb’s data sources below and access millions more through our Disclosure Search.
In 2024, the total operational greenhouse gas (GHG) emissions of Bristol-Myers Squibb amounted to 356,562 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Bristol-Myers Squibb decreased by 2.94%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
In 2024, the total Scope 1 emissions of Bristol-Myers Squibb were 206,726 metric tons of CO₂ equivalent (tCO₂e).a
Since 2019, Bristol-Myers Squibb's Scope 1 emissions have decreased by 5.25%, reflecting a declining long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2023), Bristol-Myers Squibb's Scope 1 emissions remained relatively stable, indicating that Bristol-Myers Squibb's emissions have plateaued with no significant change in its operational footprint.a
In 2024, Bristol-Myers Squibb reported Scope 2 greenhouse gas (GHG) emissions of 104,649 tCO₂e using the market-based method and 149,836 tCO₂e using the location-based method.a
Compared to the previous year (2023), Bristol-Myers Squibb's Scope 2 emissions (Location-Based) have remained relatively stable, indicating that Bristol-Myers Squibb's emissions have plateaued with no significant change in its energy consumption footprint.a
In 2024, Bristol-Myers Squibb reported its Scope 2 emissions using the market-based method and using the location-based method.a
In 2024, Bristol-Myers Squibb reported 1,700,746 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2024 disclosure of Bristol-Myers Squibb includes a breakdown across 10 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2024, Bristol-Myers Squibb reported total Scope 3 emissions of 1,700,746 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 93.44% of these emissions originated from upstream activities such as purchased goods and capital goods, while 6.56% came from downstream activities like product use, distribution, and end-of-life treatment.a
Since 2019, Bristol-Myers Squibb's Scope 3 emissions have increased by 1,546.41%, reflecting a rising long-term trend in Scope 3 emissions over time.ab
Compared to the previous year (2023), Bristol-Myers Squibb's Scope 3 emissions remained relatively stable, indicating that Bristol-Myers Squibb's emissions have plateaued with no significant change in its value chain footprint.a
In 2024, Bristol-Myers Squibb reported emissions for 10 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This reflects a high level of granularity and transparency in the company's emissions reporting.
In 2024, the largest contributors to Bristol-Myers Squibb's Scope 3 emissions were:a
In 2024, Bristol-Myers Squibb reported Scope 1 greenhouse gas (GHG) emissions of 206,726 tCO₂e and total revenues of USD 48,300 millions. This translates into an emissions intensity of 4.28 tCO₂e per millions USD.a
In 2024, Bristol-Myers Squibb reported a Scope 1 emissions intensity of 4.28 tCO₂e per millions USD. Compared to the peer group median of 4.98, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2024, Bristol-Myers Squibb ranked 10 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Bristol-Myers Squibb is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a
In 2024, Bristol-Myers Squibb reported a total carbon footprint of 2,057,308 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 2.88% decrease compared to 2023, indicating progress in reducing its overall greenhouse gas output.a
The largest contributor to Bristol-Myers Squibb's total carbon footprint was Scope 3 emissions, accounting for 82.67% of the company's total carbon footprint, followed by Scope 1 emissions at 10.05%.a